Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia
Author(s): Waller CF
Volume: 2012
Issue: default
Year: 2012
Author(s): Waller CF Volume: 2012 Issue: default Year: 2012
Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics
Author(s): Chow SC | Endrenyi L | Lachenbruch PA | Yang LY | Chi E
Volume: 2011
Issue: default
Year: 2011
Author(s): Chow SC | Endrenyi L | Lachenbruch PA | Yang LY | Chi E Volume: 2011 Issue: default Year: 2011
Biosimilars: an overview
Author(s): Bhupinder Singh Sekhon | Vikrant Saluja
Volume: 2011
Issue: default
Year: 2011
Author(s): Bhupinder Singh Sekhon | Vikrant Saluja Volume: 2011 Issue: default Year: 2011
Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia
Author(s): Mohammed A | Bagalagel A | MacDonald K | Abraham I
Volume: 2013
Issue: default
Year: 2013
Author(s): Mohammed A | Bagalagel A | MacDonald K | Abraham I Volume: 2013 Issue: default Year: 2013
Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor
Author(s): Bagalagel A | Mohammed A | MacDonald K | Abraham I
Volume: 2013
Issue: default
Year: 2013
Author(s): Bagalagel A | Mohammed A | MacDonald K | Abraham I Volume: 2013 Issue: default Year: 2013
Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia
Author(s): Bagalagel A | Mohammed A | MacDonald K | Abraham I
Volume: 2013
Issue: default
Year: 2013
Author(s): Bagalagel A | Mohammed A | MacDonald K | Abraham I Volume: 2013 Issue: default Year: 2013
Current and future biosimilars: potential practical applications in rheumatology
Author(s): Noaiseh G | Morel | L
Volume: 2013
Issue: default
Year: 2013
Author(s): Noaiseh G | Morel | L Volume: 2013 Issue: default Year: 2013
Rituximab and biosimilars – equivalence and reciprocity
Author(s): Qureshi ZP | Magwood JS | Singh S | Bennett CL
Volume: 2013
Issue: default
Year: 2013
Author(s): Qureshi ZP | Magwood JS | Singh S | Bennett CL Volume: 2013 Issue: default Year: 2013
Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases
Author(s): Desanvicente-Celis Z | Caro-Moreno J | Enciso-Zuluaga M | Anaya JM
Volume: 2013
Issue: default
Year: 2013
Author(s): Desanvicente-Celis Z | Caro-Moreno J | Enciso-Zuluaga M | Anaya JM Volume: 2013 Issue: default Year: 2013
A European perspective on the market accessibility of biosimilars
Author(s): Declerck PJ | Simoens S
Volume: 2012
Issue: default
Year: 2012
Author(s): Declerck PJ | Simoens S Volume: 2012 Issue: default Year: 2012
The development and introduction of biosimilar anticoagulants – focus on enoxaparin
Author(s): Ginsberg JS
Volume: 2012
Issue: default
Year: 2012
Author(s): Ginsberg JS Volume: 2012 Issue: default Year: 2012
Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia
Author(s): Abraham I | MacDonald K
Volume: 2012
Issue: default
Year: 2012
Author(s): Abraham I | MacDonald K Volume: 2012 Issue: default Year: 2012
